AORTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
ARTIVION, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$22.28+0.50 (+2.30%)
Close on Oct 19, 2026
- Market cap
- $1.08B
- P/E (TTM)
- –
- Dividend yield
- –
ARTIVION, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical devices | $345.83M | $290.23M | $261.19M | $230.35M | $221.60M | $179.30M | $197.25M | $187.39M | $119.63M | $113.99M | 78.4% | +19.2% |
| North America | $221.74M | $197.94M | $187.60M | $167.54M | $157.88M | – | – | – | – | – | 50.2% | +12.0% |
| EMEA | $151.37M | $131.52M | $114.81M | $104.12M | $109.08M | – | – | – | – | – | 34.3% | +15.1% |
| Preservation services | $95.51M | $98.31M | $92.82M | $83.44M | $77.24M | $73.93M | $78.98M | $75.45M | $70.07M | $66.39M | 21.6% | -2.9% |
| APAC | $44.25M | $37.20M | $33.58M | $27.97M | $21.70M | – | – | – | – | – | 10.0% | +18.9% |
| LATAM | $23.97M | $21.88M | $18.01M | $14.16M | $10.18M | – | – | – | – | – | 5.4% | +9.6% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | $345.83M | $290.23M | $261.19M | $230.35M | $221.60M | $179.30M | $197.25M | $187.39M | $119.63M | $113.99M | 78.4% | +19.2% |
| Aortic stent grafts | $159.37M | $123.08M | $107.47M | $92.75M | $85.39M | – | – | – | – | – | 36.1% | +29.5% |
| On-X | $101.74M | $83.98M | $74.53M | $63.90M | $57.36M | $48.05M | $50.10M | $44.83M | $37.04M | $34.23M | 23.1% | +21.1% |
| Preservation services | $95.51M | $98.31M | $92.82M | $83.44M | $77.24M | $73.93M | $78.98M | $75.45M | $70.07M | $66.39M | 21.6% | -2.9% |
| Surgical sealants | $76.60M | $73.90M | $68.02M | $65.38M | $70.71M | $62.07M | $68.61M | – | – | – | 17.4% | +3.7% |
| Other | $8.11M | $9.27M | $11.17M | $8.32M | $8.13M | $7.52M | $13.57M | – | – | – | 1.8% | -12.5% |
| HeRO Graft [Member] | – | – | – | – | – | – | – | – | – | $2.33M | – | – |
| BioGlue And BioFoam [Member] | – | – | – | – | – | – | – | $66.66M | $65.94M | $63.46M | – | – |
| Cardiac tissues | – | – | – | – | – | $37.89M | $40.88M | $35.68M | $32.51M | $29.70M | – | – |
| PerClot [Member] | – | – | – | – | – | $2.88M | $3.80M | $3.77M | $3.53M | $4.02M | – | – |
| Vascular tissues | – | – | – | – | – | $35.85M | $38.10M | $39.76M | $37.56M | $36.69M | – | – |
| Medical devices | – | – | – | – | – | – | $197.25M | $187.39M | $119.63M | $113.99M | – | – |
| CardioGenesis Cardiac Laser Therapy [Member] | – | – | – | – | – | $464.00K | $6.02M | $6.22M | $6.87M | $7.86M | – | – |
| ProCol [Member] | – | – | – | – | – | – | – | – | – | $218.00K | – | – |
| PhotoFix [Member] | – | – | – | – | – | $4.17M | $3.75M | $2.58M | $2.12M | $1.87M | – | – |
| International distributors | – | – | – | $47.60M | $41.05M | $34.43M | $40.43M | $36.99M | $30.81M | $32.04M | – | – |
| Domestic hospitals | – | – | – | $158.13M | $150.30M | $137.81M | $144.54M | $138.43M | $128.24M | $123.89M | – | – |
| International hospitals | – | – | – | $105.07M | $106.64M | $80.52M | $85.24M | $81.20M | $23.79M | $16.62M | – | – |
| CardioGenesis cardiac laser therapy | – | – | – | $2.98M | $850.00K | $464.00K | $6.02M | $6.22M | $6.87M | $7.84M | – | – |
| JOTEC (including NEXUS) [Member] | – | – | – | – | – | – | $64.97M | $63.34M | $4.14M | – | – | – |
| BioGlue [Member] | – | – | – | – | – | $62.07M | $68.61M | $66.66M | $65.94M | – | – | – |
| Aortic stent grafts | – | – | – | $92.75M | $85.39M | $61.66M | $64.97M | $63.34M | – | – | – | – |
| NeoPatch [Member] | – | – | – | – | – | $183.00K | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $227.26M | $198.54M | $174.52M | $152.68M | $147.69M | $114.95M | $125.67M | $118.19M | $54.60M | $48.65M | 51.5% | +14.5% |
| United States | $214.08M | $189.99M | $179.49M | $161.11M | $151.15M | $138.27M | $150.55M | $144.65M | $135.10M | $131.73M | 48.5% | +12.7% |
From the segment and revenue-disaggregation notes of Artivion's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.